Integrating metabolomics with genomics

References

• 1 Long T, Hicks M, Yu HC et al. Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat. Genet. 49(4), 568–578 (2017).
  Medline CASGoogle Scholar
• 2 Zierer J, Jackson MA, Kastenmuller G et al. The fecal metabolome as a functional readout of the gut microbiome. Nat. Genet. 50(6), 790–795 (2018).
  Medline CASGoogle Scholar
• 3 Beger RD, Dunn W, Schmidt MA et al. Metabolomics enables precision medicine: a white paper, community perspective. Metabolomics 12(10), 149 (2016).
  MedlineGoogle Scholar
• 4 Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet. 19(9), 581–590 (2018).
  Medline CASGoogle Scholar
• 5 Rotger M, Glass TR, Junier T et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin. Infect. Dis. 57(1), 112–121 (2013).
  Medline CASGoogle Scholar
• 6 Khera AV, Chaffin M, Aragam KG et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50(9), 1219–1224 (2018).
  Medline CASGoogle Scholar
• 7 Cirulli ET, Guo L, Leon Swisher C et al. Profound perturbation of the metabolome in obesity associates with health risk. Cell Metab. doi:10.1016/j.cmet.2018.09.022 (2018) (Epub ahead of print).
  MedlineGoogle Scholar
• 8 Ahima RS, Lazar MA. Physiology. The health risk of obesity – better metrics imperative. Science 341(6148), 856–858 (2013).
  Medline CASGoogle Scholar
• 9 Neeland IJ, Poirier P, Despres JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 137(13), 1391–1406 (2018).
  MedlineGoogle Scholar
• 10 Yanovski SZ, Yanovski JA. Toward precision approaches for the prevention and treatment of obesity. JAMA 319(3), 223–224 (2018).
  MedlineGoogle Scholar
• 11 Fairbrother U, Kidd E, Malagamuwa T, Walley A. Genetics of severe obesity. Curr. Diab. Rep. 18(10), 85 (2018).
  MedlineGoogle Scholar
• 12 Neavin D, Kaddurah-Daouk R, Weinshilboum R. Pharmacometabolomics informs pharmacogenomics. Metabolomics 12(7), 121 (2016).
  MedlineGoogle Scholar
• 13 Burt T, Nandal S. Pharmacometabolomics in early-phase clinical development. Clin. Transl. Sci. 9(3), 128–138 (2016).
  Medline CASGoogle Scholar
• 14 Clayton TA, Lindon JC, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073–1077 (2006).
  Medline CASGoogle Scholar
• 15 Everett JR. From metabonomics to pharmacometabonomics: the role of metabolic profiling in personalized medicine. Front. Pharmacol. 7, 297 (2016).
  MedlineGoogle Scholar
• 16 Yang Z, Marotta F. Pharmacometabolomics in drug discovery & development: applications and challenges. Metabolomics 2, e122 (2012).
  Google Scholar
• 17 Cohen IV, Cirulli ET, Mitchell MW et al. Acetaminophen (paracetamol) use modifies the sulfation of sex hormones. EBioMedicine 28, 316–323 (2018).
  MedlineGoogle Scholar
• 18 Blough ER, Wu M. Acetaminophen: beyond pain and fever-relieving. Front. Pharmacol. 2, 72 (2011).
  MedlineGoogle Scholar
• 19 Kristensen DM, Mazaud-Guittot S, Gaudriault P et al. Analgesic use – prevalence, biomonitoring and endocrine and reproductive effects. Nat. Rev. Endocrinol. 12(7), 381–393 (2016).
  Medline CASGoogle Scholar
• 20 Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA 318(19), 1925–1926 (2017).
  MedlineGoogle Scholar